Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Vivalis (Group)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are leveraged in three main areas: 1. EB66® Cell Line: VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). EB66® cell line based vaccines are currently in clinical trials in USA and in Japan. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees' net sales. 2. VIVA|ScreenTMHuman Antibody Discovery Platform: Customized solutions for the discovery, development, and production of fully human monoclonal antibodies are now offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees' net sales. 3. 3D-ScreenTMDrug Discovery Platform: VIVALIS performs discovery and development, up to pre-clinical evaluation, of original small chemical molecules identified with its proprietary platform, 3D-ScreenTM. This unique screening platform is designed to identify original molecules that alter the three-dimensional structure of a target protein, thus modulating its biological function through an innovative mode of action. VIVALIS is building a portfolio of proprietary new chemical entities for the treatment of hepatitis-C virus infection. VIVALIS also proposes, on a fee for service basis, to develop ready to use customized 3DScreenTMHTS assays directed against client's target protein of interest. Based in Nantes & Lyon (France) and in Toyama (Japan) VIVALIS was founded in 1999 by the Grimaud Group (ca. 1,500 employees), a worldwide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health, SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bioclusters and a member of the Japanese OKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama. *

 

Period Start 1999-01-01 established
Period End 2013-05-28 merged
  Group Valneva (Group)
  Today Valneva (Group)
  Successor Valneva (Group)
Product Industry avian (bird) production technology (transgenic)
Persons Person Grimaud, Franck (Vivalis 200702 CEO)
  Person 2 Mehtali, Majid (Valneva –201308 CSO before Vivalis since 2003 + Deltagen Europe + Crucell DIED 8/13)
     
Region Region Nantes
  Country France
  Street 6 rue Alain-Bombard
Campus Bio-Quest
  City 44821 Saint-Herblain Cedex, Nantes
  Tel +33-228-073710
    Address record changed: 2020-12-02
     
Basic data Employees F: 1,001 to 5,000 (2007-06-30)
  Currency EUR
  Annual sales 3,431,000 (revenue, total (2012) 2012-12-31)
  Profit -14,800,000 (2012-12-31)
  Cash 12,100,000 (2012-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2017-04-01

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Valneva (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px




» top